In a strategic move to bolster preventive oncology and enable early detection of cancer, Metropolis Healthcare Ltd., under the leadership of Ameera Shah, has launched TruHealth Cancer Screen 360, a pioneering screening initiative designed to identify early-stage malignancies through gender-specific diagnostic panels.

Positioned as a first-of-its-kind offering in India’s diagnostics sector, TruHealth Cancer Screen 360 encompasses specially curated profiles for males and females. These profiles aim to deliver actionable insights to clinicians and empower individuals to proactively manage their health. The initiative further strengthens Metropolis’s broader vision to democratise access to high-end cancer diagnostics by ensuring they are more affordable and geographically inclusive.

Addressing India’s Preventive Oncology Gap

Cancer continues to represent a pressing healthcare burden in India. According to GLOBOCAN 2022 data, the country ranks third in incidence and second in mortality in the Southeast Asia region. However, screening penetration remains alarmingly low, particularly for breast, cervical, and oral cancers, with coverage under 1%, in stark contrast to WHO’s target of 70% for cervical cancer screening. Factors like poor awareness, healthcare access gaps, and financial barriers continue to impede early detection efforts.

Metropolis aims to change this with a layered approach to screening. The TruHealth Cancer Screen 360 includes:

• Tumour markers and organ-specific assessments for early-stage identification of common cancers.
  
• Hereditary cancer risk analysis using a 317-gene NextGen panel, evaluating predisposition to over 25 cancer types.
  
• Gender-specific testing, such as PSA for prostate cancer in men and WHO-endorsed HPV self-sampling kits for cervical cancer in women, offers a convenient and private screening method that overcomes clinic visit limitations.
  
• Complimentary genetic counselling, aiding patients and their families in understanding their risk profiles and navigating further medical action.
  

Industry Leaders Speak

Commenting on the launch, Surendran Chemmenkottil, CEO of Metropolis Healthcare Ltd., stated, “With TruHealth Cancer Screen 360, we are reinforcing our commitment to preventive healthcare. The goal is to enable early detection, especially in non-urban regions where access to specialised oncology testing is limited. This is a key milestone in our broader oncology diagnostics roadmap.”

Echoing the sentiment, Dr. Kirti Chadha, Senior Oncopathologist and Chief Scientific & Innovation Officer, noted, “Traditional health check-ups often miss the early biological signs of cancer. TruHealth Cancer Screen 360 goes beyond general wellness testing by incorporating a multi-dimensional, evidence-based approach. This includes biomarkers and genetic markers that help clinicians intervene before symptoms manifest.”

Also Read :- Policy Push Urges Equitable Fertility Treatment Access in APAC Amid Declining Birth Rates

Making Precision Screening Accessible

Designed with affordability in mind, the screening profiles are being offered at an introductory price point significantly lower than the cumulative cost of individual tests. This approach not only lowers financial barriers but also drives greater adoption of comprehensive screening, an urgent need as India witnesses a concerning rise in younger, asymptomatic cancer cases, particularly in urban regions.

With an extensive test portfolio spanning 4,000+ diagnostic offerings, Metropolis Healthcare is strategically expanding its role in precision diagnostics. TruHealth Cancer Screen 360 underscores the company’s long-term commitment to early diagnosis, clinical excellence, and a preventive-first healthcare ecosystem.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!